Generic Dhivy Availability
Last updated on Aug 7, 2024.
Dhivy is a brand name of carbidopa/levodopa, approved by the FDA in the following formulation(s):
DHIVY (carbidopa; levodopa - tablet;oral)
-
Manufacturer: AVION PHARMS
Approval date: November 12, 2021
Strength(s): 25MG;100MG [RLD]
Has a generic version of Dhivy been approved?
No. There is currently no therapeutically equivalent version of Dhivy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dhivy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Levodopa fractionated dose composition and use
Patent 11,033,521
Issued: June 15, 2021
Inventor(s): Chase Thomas N & Clarence-Smith Kathleen E.
Assignee(s): AVION PHARMACEUTICALS, LLCThere is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.
Patent expiration dates:
- March 28, 2039✓✓
- March 28, 2039✓✓
- March 28, 2039✓✓
- March 28, 2039
-
Levodopa fractionated dose composition and use
Patent 11,439,613
Issued: September 13, 2022
Inventor(s): Chase Thomas N & Clarence-Smith Kathleen E.
Assignee(s): AVION PHARMACEUTICALS. LLCThere is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.
Patent expiration dates:
- March 28, 2039✓
- March 28, 2039
-
Patent 11,819,485
Patent expiration dates:
- March 28, 2039✓
- March 28, 2039
More about Dhivy (carbidopa / levodopa)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- Drug class: dopaminergic antiparkinsonism agents
- En español
Patient resources
Other brands
Sinemet, Rytary, Sinemet CR, Crexont, ... +2 more
Professional resources
Other brands
Sinemet, Rytary, Sinemet CR, Crexont, ... +2 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.